Thu, Sep 24, 3:00 PM - 4:15 PM
Virtual
ICH E9(R1) Addendum: Impact of Its Implementation
Panel Discussion (302287)
*
Frank Bretz, Novartis
*
Scott Emerson, University of Washington
*
Craig Mallinckrodt, Biogen
*
John Scott, US Food and Drug Administration
*
Robert Temple, FDA
